India: Novartis Denied Patent for Gleevec

Last Updated: 31 May 2006
Article by Manisha Singh


Patents are available only for inventions that are novel, non-obvious as well as useful. Therefore, where novelty is a bedrock concept of all patent systems, nonobviousness is the ultimate condition of patentability but first of all an invention i.e. a product of investigation and experiment must qualify as an invention. Section 3 of the Patents Act 1970 as amended by Patents (Amendment) Act 2005, in a very succinct way provides for what are not inventions. Clause (d) disqualifies a new form of a known substance which does not result in the enhancement of the known efficacy, as an invention. The Explanation further elaborates that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of the known substances are to be considered the same unless they differ significantly in properties with regard to efficacy.

In the light of this amendment made to usher India into an era of product patent regime, a new era in the Indian Pharmaceutical industry, based on innovation and new drug development, has been heralded. The instant provision of the Patents Act together with the opposition provision serves as a legal tool for both generic and pioneer pharmaceutical companies to challenge the validity of a claimed invention. The recent denial of the patent application for an anti cancer drug beta crystals of Imatinib mesylate filed by the Swiss pharma major Novartis AG and opposed by a cache of Indian pharma generic producers including Cipla and Ranbaxy, is the first major decision on patent application after India complied with the TRIPS regime in 2005 and is widely seen as a scenario of the Indian pharmaceutical industry in the product patent regime wherein opposition is an important tool to thwart off frivolous claims and also to obtain commercial benefits.


An application for patent was filed by M/s. Novartis AG on July 17, 1998 for an invention titled "Crystal Modification of A N – Phenyl – 2 Pyrimidineamine derivative, processes for its manufacture and its use" claiming Switzerland priority date of July18, 1997. The patent application in effect claimed beta crystal of methanesulphonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-pyridine-3-yl)pyrimidine-2-ylamino)phenyl]-benzamide commercially called as imatinib mesylate.

Cipla Ltd along with other generic producers filed their representation by way of opposition under section 25(1) of the Patents Act, 1970 as amended by Patents (Amendment) Act, 2005 and rule 55 of the Patents Rules, 2003 as amended by Patents (Amendment) Rules, 2005.


The arguments of the Applicant and the Opponents were on the following issues.

[1] Not an Invention

Anticipation by Prior publication


[2] Section 3(d) of the Patents Act

[3] Priority

As regards the First Issue the opponent contention was that imatinib mesylate is known from prior publications viz. Nature Medicine (May 5, 1996), Cancer Research (Vol.56, Issue I, 1996) and Blood (Nov.1 1997) besides already known from the US Patent no. 5521184 hence the subject matter of the application is anticipated the opponents tried to prove that there is no ingenuity or human intervention or novelty and inventive step in the preparation of beta crystal salt of imatinib mesylate as that is only a new form of a known substance and not an invention under the amended Patents Act.

The opponents further argued that the beta crystalline form is the most stable form of imatinib mesylate salt, which is also evident from the affidavit submitted by the applicant, which states that the beta form of the salt is thermodynamically more stable. The affidavit was based on the studies done by two reputed government institutions namely Indian Institute of Chemical Technology, Hyderabad and Indian Institute of Technology, Delhi. From their repeated studies and experiments the salt was found to steadily exist in the beta crystalline form. Also that, it is obvious for a person skilled in the art to prepare corresponding pharmaceutically acceptable salts once the freebase is known by the disclosure of the US Patent.

The applicants argued that the disclosure made in the US Patent is of the free base, ‘imatinib’ and not its salt, imatinib mesylate, therefore the present invention involves two-fold improvement over the prior art - [1] The imatinib free base is chemically changed into a salt form and [2] A particular crystal form, beta crystal form, of the salt is made through human intervention. Further that the US Patent does not give any example for the preparation of imatinib mesylate nor are there any claims made for it, however the US Patent may embrace imatinib mesylate.

It was held that the US Patent discloses methanesulphonic acid as one of the salt forming groups and the patent specification clearly states that the required acid addition salts are obtained in a customary manner. The claims 6 to 23 of the US Patent claim a pharmaceutically acceptable salt of the base compound and the patent term extension certificate, specifically mentions imatinib mesylate as the product. Thus imatinib mesylate is already known from prior publications. Also that imatinib mesylate normally exist in the beta crystals form which is thermodynamically most stable product.

Thus the opponents succeeded in proving that the invention of Novartis is obvious and anticipated by prior publication hence not an invention.

Under the Second Issue the opponents reiterated the submissions made under the first issue and further argued that the application claims only a Polymorphic form of imatinib mesylate and as regards efficacy the Patent application itself states that wherever beta crystals are used the imatinib freebase or other salts can be used equally in the treatment of diseases or in the preparation of pharmacological agents. To further corroborate the arguments, studies were conducted by technical experts to compare the relative bioavailability of the freebase with that of the beta crystal form of imatinib mesylate. A difference of 30% was found which, it was said, could be due to difference in their solubility in water. Therefore, it was argued that, the present Patent Specification does not bring out any improvement in the efficacy of the beta crystals over the known substance.

The applicant countering the argument said that section 3 (d) couldn’t be used against the subject application as the aspect of this section, that a discovery graduating into a patentable invention solely on the basis of efficiency defies logic and therefore unable to stand legal scrutiny. Further submitted that this aspect of section 3 (d) is against the tenets of the Patents Act as well as the established principals of jurisprudence and that the beta crystal form of imatinib mesylate is an invention, a new substance and not a mere discovery.

It was concluded on the basis of the above argument by the learned judge that as rightly argued by the opponents the subject matter of this application is not patentable under section 3 (d) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005.

The opponent’s contention under the Third Issue was that the patent application was filed on July 17, 1998 as a convention application claiming convention priority from an earlier Swiss application whereas Switzerland was not a convention country on that date, therefore the application deserves to be rejected on the ground of legal and technical disqualification.

The applicant responded by saying that the priority claim is discretion of the applicant and only a facility to avoid anticipation by prior publication of the invention between the priority date and filing date in India.

It was held that the patent application wrongly claims priority, hence legally and technically disqualified

In view of the above findings and all the circumstances of the case the learned judge in the instant case, Asst. Controller of Patents & Designs Mr.V.Rengaswamy, refused to proceed with the application for Patent


It was widely speculated that the product patent regime would destroy almost 15% of the existing Indian pharma market as the generic producer will have to withdraw the product when the patents controller accords patent to any of the mailbox applications. However domestic pharma companies were confident that many of these applications would not be patentable, as mailbox facility was designed to facilitate patent filings for drugs discovered between 1995 and 2005 only and that the number of new chemical entities discovered during that period is around 135 only, therefore a huge majority of the pending mail box applications would either be frivolous or those for salts, isomers, metabolites, polymers, solvents or such modification of an already patented entity.

© Lex Orbis 2006

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions